Biosimilars in the United States: Considerations for Oncology Advanced Practitioners

Biosimilars will enter the US market soon, potentially lowering costs and increasing patient access to important oncology biologics. Biosimilars are highly similar, but not identical, to their reference product. Subtle variations arise due to their inherent complexity and differences in manufacturin...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayden, Kelley D., Larson, Paul, Geiger, Danielle, Watson, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601891/
https://www.ncbi.nlm.nih.gov/pubmed/26649244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601891/
https://www.ncbi.nlm.nih.gov/pubmed/26649244

Ejemplares similares